Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
212M
-
Number of holders
-
175
-
Total 13F shares, excl. options
-
75.5M
-
Shares change
-
+1.94M
-
Total reported value, excl. options
-
$567M
-
Value change
-
+$12.7M
-
Put/Call ratio
-
0.94
-
Number of buys
-
73
-
Number of sells
-
-78
-
Price
-
$7.50
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q4 2021
220 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q4 2021.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 175 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 75.5M shares
of 212M outstanding shares and own 35.63% of the company stock.
Largest 10 shareholders include BlackRock Inc. (11.7M shares), WASATCH ADVISORS INC (11M shares), VANGUARD GROUP INC (9.34M shares), STATE STREET CORP (6.2M shares), CREDIT SUISSE AG/ (3.59M shares), GEODE CAPITAL MANAGEMENT, LLC (2.23M shares), DIMENSIONAL FUND ADVISORS LP (2.23M shares), JPMORGAN CHASE & CO (1.58M shares), Lombard Odier Asset Management (Switzerland) SA (1.54M shares), and MILLENNIUM MANAGEMENT LLC (1.3M shares).
This table shows the top 175 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.